TY - JOUR
T1 - Chemoprevention in Inherited Colorectal Cancer Syndromes
AU - Gilad, Ophir
AU - Muller, Charles
AU - Kupfer, Sonia S.
N1 - Publisher Copyright:
© 2023. Thieme. All rights reserved.
PY - 2024/4/10
Y1 - 2024/4/10
N2 - Cancer prevention in hereditary gastrointestinal predisposition syndromes relies primarily on intensive screening (e.g., colonoscopy) or prophylactic surgery (e.g., colectomy). The use of chemopreventive agents as an adjunct to these measures has long been studied both in the general population and in hereditary cancer patients, in whom the risk of malignancy, and therefore the potential risk reduction, is considerably greater. However, to date only few compounds have been found to be effective, safe, and tolerable for widespread use. Furthermore, many of the studies involving these rare syndromes suffer from small sample sizes, heterogeneous patient cohorts, short follow-up duration, and lack of standardized endpoints, creating challenges to draw generalizable conclusion regarding efficacy. The following review summarizes the current data on various chemopreventive compounds used in Lynch syndrome and familial adenomatous polyposis in addition to several agents that are currently being investigated.
AB - Cancer prevention in hereditary gastrointestinal predisposition syndromes relies primarily on intensive screening (e.g., colonoscopy) or prophylactic surgery (e.g., colectomy). The use of chemopreventive agents as an adjunct to these measures has long been studied both in the general population and in hereditary cancer patients, in whom the risk of malignancy, and therefore the potential risk reduction, is considerably greater. However, to date only few compounds have been found to be effective, safe, and tolerable for widespread use. Furthermore, many of the studies involving these rare syndromes suffer from small sample sizes, heterogeneous patient cohorts, short follow-up duration, and lack of standardized endpoints, creating challenges to draw generalizable conclusion regarding efficacy. The following review summarizes the current data on various chemopreventive compounds used in Lynch syndrome and familial adenomatous polyposis in addition to several agents that are currently being investigated.
KW - chemoprevention
KW - familial adenomatous polyposis
KW - Lynch syndrome
UR - http://www.scopus.com/inward/record.url?scp=85167655082&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85167655082&partnerID=8YFLogxK
U2 - 10.1055/s-0043-1770384
DO - 10.1055/s-0043-1770384
M3 - Review article
C2 - 38606042
AN - SCOPUS:85167655082
SN - 1531-0043
VL - 37
SP - 172
EP - 179
JO - Clinics in Colon and Rectal Surgery
JF - Clinics in Colon and Rectal Surgery
IS - 3
ER -